Elegen’s patented ENFINIA™ DNA platform uses microfluidics, AI and robotics to deliver long, clonal quality, high complexity, DNA products with unprecedented speed, low costs, and efficiency.
Elegen’s GEN II production platform delivers the speed and quality of our ENFINIA DNA products with pricing as low as $0.07/bp.
Our cell-free DNA production method utilizes less space, consumes fewer reagents, and generates less waste compared to the cell-based cloning platforms employed by our competitors. This enables us to more rapidly deliver longer, more complex DNA without compromising affordability or quality.
Rapid synthesis and production is essential for combating emerging infectious disease. Learn how mRNA templates enable fast response.
Learn how mRNA Templates enable the rapid and reliable production of patient-specific therapies.
Learn how ENFINIA linear DNA performs against traditional plasmids in cell-free protein expression kits and workflows.
FEATURED VIDEO
Produced from Elegen’s proprietary cell-free DNA production technology, ENFINIA DNA provides unprecedented speed, length, and quality. Shipped in 6 to 8 business days and up to 7 kb in length, ENFINIA DNA arrives NGS-verified with a 99.999% per base accuracy or 1:70,000 bp error rate, ready for immediate use without cloning.
FEATURED VIDEO
Introducing world’s first directed-split-pool microfluidic synthesizer with Elegen’s patented cell-free cloning technology, a unique combination of AI and robotics that fully automates the production of long, clonal quality, high complexity, double-stranded DNA with unprecedented speed, low costs, and efficiency.
Webinar
In this GEN webinar, our expert speakers will present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA as evaluated in GeneFrontier’s cell-free protein synthesis PUREfrex® system. These results showcase ENFINIA’s outperformance in terms of DNA purity, transcription efficiency, and robust protein expression for various constructs. Originally aired Wednesday October 8th 2025 aT 8A PDT.
Webinar
Join the Elegen team as we explore a cell-free approach to generating high-complexity, linear IVT-ready DNA templates—built to accelerate and scale mRNA workflows. Hosted by DDN.
Don’t miss this deep dive into faster, more consistent mRNA production. Topics include:
• Key challenges in mRNA synthesis
• A robust, cell-free alternative to plasmid prep
• Performance data comparing IVT-ready linear DNA vs. plasmid-based methods
Announcing the early access launch of Elegen’s Gen II DNA Production Platform. This platform now incorporates the world’s first directed split-pool microfluidic synthesizer, which augments Elegen’s unique cell-free cloning technology that ends the reliance on plasmids.
Oct 28, 2025
SOURCE: Businesswire
Sep 09, 2025
Elegen’s cell-free gene synthesis platform delivers full-length, high-complexity linear DNA with encoded poly(A) tails up to three times faster and free from bioburden, endotoxins and recombination-mediated variation.
SOURCE: Businesswire
SEP 04, 2025
Biocompare examines advances in upstream manufacturing technologies and processes that enable the development of more efficacious downstream products in less time.
SOURCE: Biocompare
“The growing bioeconomy demands synthetic biology performs on a scale not possible without innovation of the DNA manufacturing process. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time and capital-intensive workflows by using innovative methods and technologies to provide fast-turnaround, high-accuracy, complex, long, synthetic DNA.”
Matthew Hill
Founder and CEO of Elegen
